ArticleInternational journal of cancer2026
Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anal HPV in Kidney Transplant Recipients: A Closer Look at Pathogenesis and Clinical Management.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Solid organ transplant recipients (SOTRs) have an elevated risk of persistent infection of human papillomavirus (HPV) and associated anogenital (cervical, vulva, and vaginal among women, penile among men and anal among both men and women) cancers. Risk stratification and temporal trends of cancer incidence will help early detection, evaluation, management, and treatment of post-transplant cancers over time. We analyzed data of 239,613 heart, lung, liver, and kidney transplant recipients registered from 1987 to 2020 in the U.S. Scientific Registry of Transplant Recipients (SRTR) with cancer diagnosis reported during follow-up. There were 693 new cases of HPV-associated anogenital cancers, including 176 anal, 118 cervical, 310 vulvar, and 89 penile cancers. The age-adjusted incidence rates and confidence intervals (IRs [95% CI] per 100,000 person-years) were anal (10.5 [9.1, 12.2]), cervical (17 [14.2, 20.4]), vulvar (44.2 [39.5, 49.4]), and penile (9.0 [7.3, 11.1]). Overall, the risk of all cancers among SOTRs remains elevated compared with the U.S. general population: standardized incidence ratio (SIR) for anal (2.73 [2.34, 3.14]), cervical (1.46 [1.21, 1.73]), vulvar (8.82 [7.87, 9.83]), and penile (6.13 [3.38, 9.70]). Lung recipients showed the highest IR for anal, vulvar, and penile cancer, while heart recipients demonstrated the highest IR for cervical cancer. Similarly, the 10-year cumulative incidence (per 100,000 persons) of anal (124), vulvar (523) and penile (95) cancer was highest among lung recipients, while the highest cumulative incidence of cervical cancer (231) was among heart recipients. These data can help develop risk stratification for HPV-associated cancer screening and management among SOTRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.